SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: old 'n cranky who wrote (10046)4/9/2018 3:22:42 PM
From: HardToFind  Read Replies (1) | Respond to of 12873
 
You may be right that it will cost more than $4 million in direct costs. That may be an overly optimistic price. It could be 3x that price or more. It will largely depend on Phase III population size required. Getting test patients to put on a low-toxicity topical creme to make their herpes outbreak (shingles, genital or oral) go away quickly should not be very difficult or expensive relative to an average clinical trial.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News